Powerful perspectives
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press release
iOnctura commences randomized Phase II study in metastatic uveal melanoma
Press release
iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair
Press release
iOnctura reaches new clinical milestones in uveal melanoma
Press release
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
Press release
€80 million Series B financing to progress pipeline through Phase II trials
Press release
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
Press release
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023
Press release
iOnctura to present research on roginolisib and IOA-359 at ASH
Press release
iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Press release
New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer
Press release
iOnctura to present research at leading scientific conferences in June 2023
Press release
Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer
Looking for media
resources?